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Abstract
The Infectious Disease Society of America (IDSA) publishes guidelines regularly for the man-
agement of skin and soft tissue infections; however, the extent to which practice patterns fol-
low these guidelines and if this can affect treatment failure rates is unknown. We observed the
treatment failure rates from a multicentre retrospective ambulatory cohort of adult emergency
department patients treated for a non-purulent skin infection. We used multivariable logistic
regression to examine the role of IDSA classification and whether adherence to IDSA guide-
lines reduced treatment failure. A total of 759 ambulatory patients were included in the cohort
with 17.4% failing treatment. Among all patients, 56.0% had received treatments matched to
the IDSA guidelines with 29.1% over-treated, and 14.9% under-treated based on the guide-
lines. After adjustment for age, gender, infection location and medical comorbidities, patients
with a moderate infection type had three times increased risk of treatment failure (adjusted
risk ratio (aRR) 2.98; 95% confidence interval (CI) 1.15–7.74) and two times increased risk
with a severe infection type (aRR 2.27; 95% CI 1.25–4.13) compared with mild infection
types. Patients who were under-treated based on IDSA guidelines were over two times
more likely to fail treatment (aRR 2.65; 95% CI 1.16–6.05) while over-treatment was not asso-
ciated with treatment failure. Patients ⩾70 years of age had a 56% increased risk of treatment
failure (aRR 1.56; 95% CI 1.04–2.33) compared with those <70 years. Following the IDSA
guidelines for non-purulent SSTIs may reduce the treatment failure rates; however, older
adults still carry an increased risk of treatment failure.
Introduction
There has been a dramatic increase in the prevalence and severity of skin and soft tissue infec-
tions (SSTIs) in the USA over the past two decades [1]. SSTIs are the second most common
infection type leading to hospitalisation in the USA [1–3]. There are roughly 6.3 million phys-
ician office visits per year for SSTIs [4], and between 1993 and 2005, annual visits for SSTIs in
US emergency departments (ED) increased from 1.2 to 3.4 million [5]. Non-purulent cellulitis,
a common cause of SSTIs, remains poorly understood due to the lack of rapid microbiological
diagnosis and remains a clinically diagnosed condition. Historically, the vast majority of cel-
lulitis has been caused by streptococci bacterial species, often group A along with methicillin-
sensitive Staphylococcus aureus [6, 7]. Methicillin-resistant S. aureus (MRSA), a common spe-
cies causing purulent SSTIs, is an uncommon organism causing cellulitis [6], and β-lactam
monotherapy remains the recommended first-line choice for non-purulent skin infections
[8]. Antibiotics targeting MRSA are only needed in selective patient populations [8]. This is
supported by recent randomised clinical trials of patients with cellulitis demonstrating no add-
itional benefit of adding MRSA coverage to β-lactam treatment [9, 10]. Clinicians in the USA,
however, prescribe antibiotic regimens that include MRSA coverage for cellulitis approximately
63% of the time in the outpatient setting [11]. Despite the multiple antibiotic classes available
for the treatment of cellulitis, it has a high treatment failure rate with, on average, 20% of cel-
lulitis patients involved in clinical trials failing treatment [12, 13].
In response to the high failure rates of cellulitis and all SSTI patients, in 2014, the Infectious
Disease Society of America (IDSA) updated their guidelines for the management of SSTIs [8].
These guidelines focused on ‘promptly diagnosing SSTIs, identifying the pathogen and admin-
istering effective treatments in a timely fashion’ [8]. With an algorithm defining infection
severity type and matching this to antimicrobial treatment, the guidelines simplify the
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management of SSTIs. The 2014 guidelines were a departure from
previous versions with the creation of a treatment algorithm for
three categories of SSTI severity (mild, moderate and severe)
with specified treatment regimens assigned to each category.
The severity categories are defined mainly by the patient’s medical
comorbidities (such as those with markedly impaired host
defences), recent antibiotic use and severity of presenting symp-
toms. Despite these recommendations, clinicians typically have
done a poor job in following these guidelines with adherence
rates <50% [14, 15]. We have previously reported that adherence
to these algorithms are poor with physicians following the guide-
lines for the treatment of purulent skin infections less than half of
the time [14, 15]. Others have noted a similar striking lack of con-
cordance with IDSA guidelines for both purulent and non-
purulent types [16]. There is however limited literature examining
real-world clinical outcomes in patients where the clinician either
followed or departed from the IDSA guidelines.
The purpose of this retrospective cohort study was to assess the
effectiveness of following the IDSA guidelines for the treatment of
cellulitis in the outpatient setting through a descriptive analysis of
the treatment and outcomes of ED patients from one large teach-
ing and three smaller community hospitals. The objectives of this
study were to: (1) describe the frequency with which treatment
failure occurs among adults treated and discharged home from
one of four EDs and the frequency with which clinicians practice
patterns followed the severity classification treatment recommen-
dation indicated in the 2014 IDSA guidelines for non-purulent
skin infection; (2) evaluate whether not following the IDSA guide-
lines was an independent risk factor for treatment failure; and (3)
evaluate other patient/treatment characteristics associated with
treatment failure.
Methods
Study setting and population
We conducted a multicentre, retrospective cohort study. We iden-
tified patients 18 years and older who presented for treatment of a
non-purulent skin infection between April and November in 2014
to one urban tertiary care academic centre with an annual ED cen-
sus of 132 000 visits or any of three community EDs with a com-
bined annual ED census of 100 000 visits. Patients were included in
the study if they were discharged from the ED or the ED observa-
tion unit with a diagnosis of a skin or soft tissue non-purulent
infection pulled from the electronic medical record discharge diag-
noses listed. All patients were classified as having a suspected non-
purulent infection based on discharge diagnoses. Patients already
on antibiotics from a source outside of the ED were included
(e.g. primary care office). Patients were excluded if they underwent
an incision and drainage with expression of purulent material, if
they were admitted to the hospital on their initial visit, or if they
did not have follow-up visit data. Additionally, we excluded
patients with a post-surgical infection, infections of the oral cavity
or hidradenitis suppurativa. Patients with hidradenitis were
excluded because they were not expected to improve without fur-
ther surgical intervention. This study was approved by the institu-
tional review board (IRB docket H00007714).
Data collection
To reduce the potential for systematic error and to mitigate bias,
we followed protocols for the optimal conduct of retrospective
studies [17]. Prior to data abstraction activities, we a priori
defined the pertinent predictor and outcome variables to be col-
lected in a standardised manner. Abstractors were uniformly
trained by the investigators and blinded to the study objectives
and hypotheses. We utilised two different abstractors for each
patient enrolled, the first one collecting data on the initial ED
visit, recording demographic, historical and clinical data, while
the second abstractor collected all follow-up visit data that
included the principal study outcome variables. Abstractors met
regularly with the investigators to review the coding rules. The
investigators performed an inter-rater reliability assessment on a
10% random sample of charts.
Variable measurement
Baseline variables were extracted by the first abstractor from the
initial ED visit including socio-demographic characteristics, med-
ical history, chief complaint and previous antibiotic use. The
Charlson Comorbidity Index (CCI) was calculated and used to
rank patient’s medical comorbidities [18, 19]. Information per-
taining to initial ED presentation, ED course and antibiotic treat-
ments rendered was also recorded. Starting from this initial visit,
all subsequent medical visits, within a 60-day window pertaining
to this index infection, were reviewed by a second abstractor also
using the electronic medical records. Follow-up chart review was
performed by a different abstractor using electronic medical
records recording any clinical visits 1 month after the initial ED
visit.
Outcomes
Our main outcome was overall treatment failure. Treatment fail-
ure was determined upon follow-up after ED discharge and
defined as: any change to the initial antibiotic regimen after
24 h, including increased duration of treatment, type, dose or
route of antibiotic instituted (i.e. need for intravenous antibiotics
after oral treatment); admission to a hospital ward or observation
unit for additional treatment; or any surgical procedures needed
for treatment of the infection. The definition of treatment failure
was determined a priori by the authors based on their previous
experiences and literature on this topic [15]. If a patient met
any of the above described criteria, their outcome was categorised
as treatment failure, otherwise they were categorised as clinical
cure. Our secondary outcome measure was admission to the hos-
pital for treatment of the infection with a change in medical treat-
ment. We assessed admission separately because we considered
this an indication of a more severe form of failure with greater
healthcare ramifications for the individual patient. All patients
without documentation of treatment failure but with continued
documentation or repeat visits in the medical record were classi-
fied as clinically cured.
IDSA classification
We used IDSA guidelines to classify the severity of each patient’s
non-purulent skin infection upon presentation and the observed
ED treatments [8]. Each case was categorised into one of three
categories of non-purulent SSTIs: mild, moderate or severe as
defined by the IDSA guidelines. We have previously used the
IDSA guidelines in a similar retrospective chart review format
[14, 15]. In brief, these guidelines define a mild infection as an
uncomplicated infection without any signs of systemic infection,
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a moderate infection as one where the patient has signs of a sys-
temic infection, and a severe infection when the patient has either
signs of systemic inflammatory response syndrome (SIRS), an
impaired host defence, associations with penetrating trauma,
was an injection drug user or had evidence of MRSA infection
elsewhere. Screening ambulatory patients for nasal colonisation
with MRSA is not done in the ED and thus this condition
could not be included in the severe category. We defined signs
of systemic infection by the presence of fever either reported by
the patient or recorded in the ED with a temperature >38.0 °C.
We defined SIRS as the presence of one of the following: heart
rate >90 beats per minute, respiratory rate >20 breaths per minute,
temperature >38.0 °C, white blood count >12 000 cells/mm3,
white blood count <4000 cells/mm3 or presence of >10% imma-
ture neutrophils.
The presence or absence of antibiotic classes and route of
administration (intravenous or oral) determined the treatment’s
categorisation as mild, moderate or severe treatment class accord-
ing to IDSA treatment recommendations [8]. We used the 2014
IDSA guidelines to compare the observed antibiotic treatment
regimens to the expected regimens according to these guidelines.
Accordingly, each patient received a score of 1 for mild, 2 for
moderate and 3 for severe for their infection at the initial ED
visit presentation and a second score for the treatments rendered.
We then compared the clinical presentation and treatment scores
with each other to determine if the observed matched the antici-
pated treatment class or if the patient was either over or under-
treated. This formed our guideline concordant treatment index.
In this index, we categorised patients into the matched group
when the scores equalled each other, under-treated if the observed
score was lower than the expected score and over-treated when
the observed score was higher than the expected score.
Data analysis
We used χ2 tests to compare categorical variables, and the stu-
dent’s t test for continuous variables, between patients with clin-
ical cure and those that failed treatment. We did the same for the
secondary outcome of hospital admission. Given the large sample
size, data were assumed to be normally distributed. We utilised
multiple-imputation which replaces missing values with multiple
sets of simulated values to complete the data to address missing
data in our dataset, assuming data were missing at random.
Data here were missing in <5% of key variables without discern-
able patterns.
We used multivariable logistic regression analysis to test
whether or not the IDSA severity score and guideline concordant
treatment index were associated with treatment failure. The IDSA
severity score and guideline concordant treatment index were the
main variables of interest. To select the set of covariates for the
multivariable model, we first determined important a priori cov-
ariates that we thought would have clinical relevance based on the
literature. Covariates included patient demographics, infection
characteristics and antibiotic classes of medications [14, 15].
Patient demographics included age, gender and patient comorbid-
ities (CCI score). Age was included as a continuous variable in the
initial model and also used as a categorical variable with a cut-
point of ⩾70 years of age or not determined a priori. We chose
70 years as an elderly age cut-off based on the changing profile
of health [20] and increased mortality [21] seen starting at that
age. The infection characteristics included location and the pres-
ence of proximal streaking. Any covariates with a P < 0.10 from
unadjusted bivariate analyses were included (this resulted in
facial, extremity and genital location being included in the
model). The antibiotic classes with a P < 0.10 in the bivariate ana-
lyses were Vancomycin and third-generation Cephalosporin;
however, they were not included in the multivariable model
because they were both used to define the IDSA treatment cat-
egories and thus would have been collinear with this variable.
To analyse the effect of patients lost to follow-up, we per-
formed a sensitivity analysis using best-case and worst-case scen-
arios where we reran the model with the patients lost to follow-up
first coded as none having failed treatment and then again with
them coded as all having failed treatment. We used Stata
Version 13.1 (StataCorp LP, College Station, TX, USA) for all
analyses.
Results
Characteristics of the study subjects
During the 8-month study period in the four ED sites, there were
a total of 903 patients treated and discharged home with a diag-
nosis of a non-purulent SSTI of which 104 (11.5%) were ultim-
ately lost to follow-up (Fig. 1). An additional 40 patients were
excluded on secondary chart review because an incision and
drainage was performed, thus making the infection type purulent.
Thus, out of the final cohort of 759 eligible patients, 132 (17.4%)
failed treatment. We had an inter-rater reliability κ for all vari-
ables used in this analysis of at least 0.92.
The final study cohort had an average age of 47.8 (S.D.; 18.6)
years with 13.9% being 70 years of age or older, 46.1% female
and 23.6% having been treated prior to their ED visit for the
same infection. Patients that failed treatment after their ED visit
were older in age, with infections primarily involving an extremity
not including the structures of the hand (Table 1). Women were
29% less likely than men to fail treatment (risk ratio (RR) of 0.71;
95% confidence interval (CI), 0.51–0.98) and infections of the face
were 61% less likely to fail (RR 0.39; CI 0.22–0.85). We did not
note any differences among patients with infections related to
intravenous drug abuse, previous treatment for the same infection
or currently on antibiotics.
Treatments rendered in the ED
Treatments rendered in the ED consisted of 39.1% of patients
receiving intravenous antibiotics. The most common type of
intravenous antibiotic used was vancomycin (glycopeptide) with
50.0% of patients receiving this class of antibiotic followed by
17.5% clindamycin (lincomycin), 10.4% third-generation cephalo-
sporin, 8.1% first-generation cephalosporin, 6.4% aminopenicillin
and 4.1% extended-spectrum penicillin. Among patients that
received intravenous antibiotics in the ED (Table 2), patients trea-
ted with either a third-generation cephalosporin (RR 1.92; CI
1.13–3.29) or vancomycin (RR 1.38; CI 0.97–1.95) had an
increased risk of treatment failure. There were 76 (10.0%) patients
that were placed in ED observation status to receive multiple
rounds of antibiotics before being discharged home. We did not
detect any differences in treatment failure among the different
classes of antibiotics prescribed for home (Table 2). Of note,
using a single or combination of antibiotic classes covering
MRSA did not change the proportion of patients that failed treat-
ment. The most common MRSA antibiotic regimen included the
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combination of a first-generation cephalosporin with a sulfona-
mide, which occurred in 16.5% of ED patient encounters.
Infection severity and treatment classifications compared with
IDSA guidelines
Using the data collected from the patients at the time of ED pres-
entation, which included medical history and symptom severity
variables, we classified the IDSA SSTI severity type. The majority
of patients seen and discharged home had a mild infection type
(76.8%), while 9.2% had a moderate and 14.0% had a severe infec-
tion type. Using medication administration data, we classified the
treatment rendered as either a mild, moderate or severe class.
Patients received mild antibiotic treatment 60.8% of the time,
while 19.6% received moderate and 19.5% severe antibiotic treat-
ment class. All patients that received severe IDSA classification
antibiotic treatment did so due to the administration of intraven-
ous vancomycin. Comparing the IDSA severity class to the IDSA
treatment class, we determined the proportion of patients that
received treatments that matched IDSA guidelines vs. those that
were either under or over-treated (Table 3). Guideline concordant
treatment resulted in a 26% reduction in the risk of subsequent
treatment failure (RR 0.74; CI 0.54–1.01) compared with not fol-
lowing the guidelines. Patients that were over-treated accounted
for more treatment failures (Table 3).
Multivariable associations with treatment failure
In our multivariable logistic regression, which combined a priori
clinical variables and covariates with a P < 0.10, patients presenting
with IDSA scores of moderate and severe had more than twice the
risk of treatment failure than those with a mild severity score
(Table 4). When evaluating the guideline concordant treatment
index, under-treating patients resulted in more than twice the
risk of treatment failure while over-treatment did not increase or
decrease the patient’s risk after adjustment for the other covariates.
The only other variable that was significantly associated with an
increased risk of failure was patient age. For every decade of life,
there was a 10% increase in the associated risk of treatment failure
after adjusting for the other covariates which include IDSA score
and under/over-treatment (Table 4). Using age as a categorical
variable resulted in patients ⩾70 years being 56% more likely to
fail treatment (RR 1.56; CI 1.04–2.33) than those <70 years after
adjusting for the other covariates. The significance of the IDSA
score, under-treatment and elderly patients having greater risk of
failing treatment did not change in the sensitivity analyses.
We ran a second logistic regression model replacing the pri-
mary outcome of treatment failure with the secondary outcome
of subsequent hospital admission. In doing so, the variables that
were significant in the first model remained so, and the associated
risks with patient age ⩾70 years (RR 2.53; CI 1.26–5.07), severe
infection type (RR 5.69; CI 2.25–14.22) and under-treatment
(RR 3.82; CI 1.06–13.72), all increased considerably
(Supplemental Table S1).
Discussion
Failing initial ED outpatient treatment for a non-purulent skin
infection was significantly associated with both the IDSA severity
class and under-treatment according to the 2014 IDSA guideline
concordant treatment index. Our findings are among the first to
highlight the importance of clinicians strictly following the treat-
ment algorithms put forth by the IDSA to reduce the risk of SSTI
treatment failure. We did however find that advancing age was an
independent risk factor for treatment failure. Patients aged ⩾70
years had a 56% increased risk of failing antibiotic treatment
even after adjusting for the infection severity type and whether
the IDSA recommended guidelines for treatment were followed.
Our findings suggest that advanced age should be considered in
future treatment guidelines to better reduce the risk of treatment
failure in older individuals with non-purulent skin infections.
SSTIs have high treatment failure rates
Our failure rate of 17.4% is consistent with failure rates of 15–20%
using clinical trial data [9, 13, 22]. ED-based studies have found
Fig. 1. Study enrolment flow chart. SSTI, skin and soft tissue infec-
tions; I&D, incision and drainage.
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that between 18.7% and 20.5% of patients prescribed antibiotics
fail treatment requiring either subsequent hospital admission,
additional intravenous treatment or a change in the class of anti-
biotics prescribed [23, 24]. Because cellulitis consumes consider-
able resources to treat and fails treatment quite often, a better
approach to standardise its treatment is needed.
Clinicians have low levels of adherence to treatment guidelines
In this investigation, treatment aligned with the IDSA recommen-
dations in just over 50% of ED patients. Experiences of clinicians
having low levels of adherence to published guidelines are not
unique to the USA or SSTIs. In Europe, the Clinical Resource
Efficiency Support Team (CREST) publishes guidelines similar
to the IDSA for treatment of cellulitis, but when studied in prac-
tice clinicians still over-treat 43% of the time [25, 26]. In the USA,
one in three antibiotics prescribed in the ambulatory setting are
inappropriate [27]. The Centers for Disease Control and
Prevention predict that at least 50% of antibiotics prescribed for
acute respiratory conditions are unnecessary [28], while it has
been shown that only 52% of antibiotic prescriptions given for
sinus infections, middle ear infections and pharyngitis match
recommendations based on established guidelines [29]. This
inappropriate and excessive treatment with broad-spectrum anti-
biotics leads to antimicrobial resistance and has never been shown
to improve clinical outcomes. We have shown here that patients
that were over-treated did not have a reduction in failure risk;
however, those that were under-treated did have an increased
risk. This demonstrates how following the IDSA guidelines
leads to fewer treatment failures and can reduce unnecessarily
broad antibiotic use. A next logical approach would be to pro-
spectively apply these guidelines in the clinical setting to deter-
mine if changing practice to better align with the IDSA
guidelines results in a reduction in treatment failures.
The elderly have an increased risk of treatment failure
Advancing age is an important clinical factor to take into account
when treating patients for bacterial infections and has been
included in other treatment algorithms such as those for the treat-
ment of community-acquired pneumonia [30, 31]. Patient’s age is
not included in the IDSA SSTI algorithms. Here, we found that
Table 2. Treatment outcome by antibiotics characteristics
Type
Clinical cure
(n = 623)
Treatment
failure
(n = 136)
P valuen % n %
IV ED Abx
Vancomycin 114 (18.3) 34 (25.0) 0.08
Clindamycin 40 (6.4) 12 (8.8) 0.26
Cephalosporins 3rd 21 (3.4) 10 (7.4) 0.026
Cephalosporins 1st 20 (3.2) 4 (2.9) 0.92
Aminopenicillin 17 (2.7) 2 (1.5) 0.42
Extended-spectrum
PCN
10 (1.6) 2 (1.5) 0.95
ED Observation 63 (10.1) 13 (9.6) 0.95
Home Abx
Sulfonamide 148 (23.8) 40 (29.4) 0.11
Cephalosporins 1st 144 (23.1) 28 (20.6) 0.66
Lincomycin 116 (18.6) 24 (17.6) 0.93
Tetracyclines 42 (6.7) 9 (6.6) 0.96
Aminopenicillins 37 (5.9) 3 (2.2) 0.09
Fluroquinolones 10 (1.6) 0 (0.0) 0.14
Penicillin 8 (1.3) 1 (0.7) 0.62
Metronidazole 4 (0.6) 0 (0.0) 0.36
MRSA coverage 217 (34.8) 49 (36.0) 0.58
Cephalosporins +
sulfonamide
100 (16.1) 25 (18.9) 0.40
IV, intravenous; Abx, antibiotics; ED, emergency department; PCN, penicillin; MRSA,
methicillin-resistant Staphylococcus aureus.
Data are presented as n (percentages) unless otherwise indicated.
Table 1. Characteristics of study patientsa
Demographics
Clinical cure
(n = 623)
Treatment
failure (n = 136)
Pn % n %
Age (S.D.) 47.1 (18.6) 50.6 (17.9) 0.034
Age ⩾70 81 (13.0) 25 (18.4) 0.07
Female 300 (48.2) 50 (37.8) 0.037
White 555 (89.1) 120 (88.2) 0.13
Hispanic 41 (6.6) 3 (2.2) 0.97
African
American
21 (3.4) 8 (5.9) 0.60
Asian 10 (1.6) 1 (0.7) 0.71
Medical history
CCI 0 451 (72.4) 94 (69.1) 0.87
CCI 1 106 (17.0) 25 (18.4) 0.57
CCI 2 50 (8.0) 12 (8.1) 0.67
CCI 3 or more 20 (3.2) 1 (0.7) 0.12
Current IVDA 24 (3.9) 6 (4.4) 0.70
Currently on
Abx.
152 (24.4) 27 (19.9) 0.25
Infection
characteristics
Face 89 (14.3) 8 (5.9) 0.011
Trunk 39 (6.3) 5 (3.7) 0.28
Hand 89 (14.3) 16 (11.8) 0.53
Extremity,
not hand
384 (61.6) 93 (68.4) 0.047
Buttocks 8 (1.3) 3 (2.2) 0.38
Genitals 13 (2.1) 6 (4.4) 0.09
Fever 66 (10.6) 12 (8.8) 0.43
CCI, Charlson comorbidity index; IVDA, intravenous drug abuse; Abx, antibiotics.
aData are presented as n (percentages) unless otherwise indicated.
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elderly patients treated and discharged home had a 56% increased
risk of treatment failure and almost three times the risk of admis-
sion after adjusting for adherence to the IDSA guidelines. Age is
an important variable to consider given that elderly patients’
immune system defence mechanisms weaken over time making
them more susceptible to many types of bacterial infections
when compared with younger adults [32]. Combining this with
the fact that SSTIs are common in the elderly [33] makes defining
differential treatment decisions by age essential to reducing failure
rates. The way in which clinicians should treat elders with a non-
purulent infection differently from younger patients (i.e. anti-
biotic class or route choice, admission) still needs defining, and
presents an important area for future work.
Study strengths and limitations
Our study has some limitations. First, this is a retrospective cohort
study design, which may introduce selection and information
biases. However, results from sensitivity analyses suggest that
selection bias from loss to follow-up did not influence the main
effects of IDSA treatment and age on the outcome of treatment
failure. We also used discharge diagnosis rather than ICD codes
which may have missed some patients that would have been
included using ICD codes. However, we attempted to limit this
by looking at all possible relevant discharge diagnoses (i.e. sepsis)
to ensure we did not miss these patient types. Second, clinicians
have had difficulty in appropriately diagnosing cellulitis [34],
which may have led to misclassification of the eligibility criteria.
We did not attempt to adjust for this type of misclassification
in order to observe how the guidelines perform in real-life clinical
practice. Another limitation is the way in which we defined signs
of systemic infection, that being the presence of a fever. It is pos-
sible that in practice clinicians may use other data sources than
fever alone to make treatment determinations aligning with the
IDSA moderate infection type, which are just not available
through review of the medical record. Another limitation is that
follow-up was done through chart review that did not include
facilities outside of our medical record. We attempted to limit
this by reviewing primary care notes for all patients to probe to
see if the patient was seen at another facility. Additionally, we
excluded patients if they did not have follow-up visit data.
Finally, the majority of patients whose ED treatment was classi-
fied under the severe category were done so due to the inclusion
of intravenous vancomycin into their treatment regimen. In the
IDSA guidelines, vancomycin plus another class of antibiotics
places the treatment under the severe category unless culture sen-
sitivities are available, which is often not the case in the ED. It
may be that either one of two doses of vancomycin are inappro-
priate treatment before discharge; however, we did not detect this
association in our bivariate analysis nor is this stipulated in the
guidelines. This study’s balancing strengths are that it is the
first to examine concordance with IDSA SSTI guidelines in rela-
tion to patient outcomes in practice in a large cohort of patients
treated from multiple sites that include both academic and com-
munity settings.
Conclusions
In summary, our findings suggest that adherence to the IDSA
guidelines for non-purulent SSTIs can reduce the treatment fail-
ure rate among ambulatory patients, thus improving their care
and reducing unnecessary antibiotic use. The next step is to pro-
spectively apply these guidelines and observe the treatment failure
rates pre- and post-intervention. By educating and developing
simple aids to guide clinicians, we might start to improve both
adherence rates and patient outcomes. Further, our study suggests
that advancing age is an important clinical factor to include in
future SSTI treatment guidelines given the increased prevalence
and treatment failure rates among this vulnerable group of
patients. Adjusting antimicrobial treatment among the elderly
may be an important avenue to further reduce the treatment fail-
ure rates that have historically been associated with non-purulent
SSTI outcomes.
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Table 3. Treatment outcome by IDSA guideline comparisons
Type
Clinical cure
Treatment
failure
P
valuen % n %
Mild 484 (77.7) 99 (72.8) 0.15
Moderate 54 (8.6) 16 (11.8) 0.35
Severe 85 (13.6) 21 (15.4) 0.33
Followed
guidelines
361 (57.9) 64 (47.1) 0.06
Over-treated 174 (27.9) 47 (34.5) 0.07
Under-treated 92 (14.8) 21 (15.4) 0.72
Data are presented as n (percentages) unless otherwise indicated.
Table 4. Factors significantly affecting the risk of treatment failure from
multivariable logistic regression
Risk ratio 95% CI P-value
Age (10 years) 1.10 (1.01–1.20) 0.031
Above 70 1.56 (1.04–2.33) 0.029
Female 0.77 (0.54–1.04) 0.08
Previous Abx 0.74 (0.50–1.08) 0.12
CCI score 0.85 (0.69–1.04) 0.12
Facial location 0.53 (0.25–1.11) 0.09
Extremity 1.17 (0.79–1.73) 0.42
Genitals 1.72 (0.84–3.55) 0.14
Moderate symptoms 2.98 (1.15–7.74) 0.025
Severe symptoms 2.27 (1.25–4.13) 0.007
Over-treat 1.76 (0.85–3.66) 0.13
Under-treat 2.65 (1.16–6.05) 0.021
Abx, antibiotics; CCI, Charlson comorbidity index.
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